Luis Quintanilla, Juan Song, Jeremy Simon, Ya-Dong Li, Brent Asrican, Seth Tart, Yan-Jia Luo, Yijing Su, Hongjun Song, Ryan N. Sheehy, Guo-Li Ming
Dongshu Liu, Suhe Dong, Cong Liu, Jicong Du, SiNian Wang, Huijie Yu, Wei Li, Zhongmin Chen, Renjun Peng, Qisheng Jiang, Mengying Zou, Fengsheng Li, Rong Zhang
Pronamee Borah, Nitin Dayal, Sangeeta Pathak, Rahul Naithani
Xiaohong Zhao, Xue Li, Ying Wang, Yicheng Guo, Yong Huang, Dalun Lv, Mingxing Lei, Shicang Yu, Gaoxing Luo, Rixing Zhan
Alec B Chaves, Donghai Zheng, Jonathan A Johnson, Bryan C Bergman, Zachary W Patinkin, Vincent Zaegel, Ericka M Biagioni, Polina Krassovskaia, Nicholas T Broskey, Linda E May, Dana Dabelea, Joseph A Houmard, Kristen E Boyle
Xinyang Li, Zhenyu Xie, Yinde Huang, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Wenbin Chen, Yuchen He, Jian Zhang
Old dogs may not learn new tricks, but old drugs can, according to a research team based in China.
Poor healing of cutaneous wounds is a common medical problem in the field of traumatology. Due to the intricate pathophysiological processes of wound healing, the use of conventional treatment methods, such as chemical molecule drugs and tradit
BACKGROUNDDiabetes mellitus (DM) is a serious and growing global health burden. It is estimated that 80% of diabetic patients have micturition problems such as poor emptying, urinary incontinence, urgency, and urgency incontinence. Patients wit
BACKGROUNDHuman Wharton’s jelly-derived mesenchymal stromal/stem cells (hWJ-MSCs) have gained considerable attention in their applications in cell-based therapy due to several advantages offered by them. Recently, we reported that hWJ-MSCs an
Pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine, inhibit glutathione metabolism. These drugs decrease the aggressiveness of pancreatic cancer, inhibit tumor stem cell survival, and reduce chem
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.
Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced publication of its research in the peer-reviewed journal Autophagy which support pridopidine’s potential neuroprotective properties by enhancing autophagy in an amyotrophic lateral sclerosis (ALS) model.
A stomach adult stem cell population can fulfill two distinct functions: either help with digestion under normal conditions or take the lead on injury response.
Yi Liu, Bowen Zheng, Yuan Zhong
TianLei Xie, Zhongqing Zhang, Wenmin Cao, Wei Chen, Hongqian Guo, Junlong Zhuang
Lijun Wang, Lihui Wang, Rongli Wang, Ting Xu, Jingyuan Wang, Zhiwei Cui, Feiyan Cheng, Wei Wang, Xinyuan Yang
Daniel Richard, Steven Pregizer, Divya Venkatasubramanian, Pushpanathan Muthuirulan, Zun Liu, Terence D. Capellini, April M. Craft
Seven new innovators representing five clean energy startups will join Chain Reaction Innovations, Argonne National Laboratory’s entrepreneurship program, as part of the elite program’s sixth cohort.
Fabiën Belle, Tomáš Sláma, Christina Schindera, Tamara Diesch, Mutlu Kartal-Kaess, Claudia Kuehni, Luzius Mader
Raquel Rua Martins, Michael Rera, Catarina M. Henriques
Tahir Haideri, Alessandro Howells, Yuqian Jiang, Jian Yang, Xiaoping Bao, Xiaojun Lian
Yaiza Nunez-Alvarez, Tristan Espie--Caullet, Reini F Luco
Belen Alvarez-Palomo, Anna Veiga, Angel Raya, Margarita Codinach, Silvia Torrents, Laura Ponce Verdugo, Clara Rodriguez-Aierbe, Leopoldo Cuellar, Raquel Alenda, Cristina Arbona, Dolores Hernández-Maraver, Cristina Fusté, Sergi Querol
Hojjatollah Nazari, Asieh Heirani, Masoud Soleimani, Reza Akbari Asbagh, Behnam Behboudi, Mohammad Sadegh Fazeli, Mojgan Rahimi, Mohammad Reza Keramati, Amir Keshvari, Alireza Kazemeini, Foroogh Alborzi, Seyed Mohsen Ahmadi Tafti
Yuki Nakafusa, Naoyoshi Nitta, Kazunari Ishii, Naoto Shirasu, Takahiro Iwamoto, Takayuki Nemoto, Masafumi Nakamura, Masafumi Goto, Hiroo Iwata, Masaru Taniguchi, Yohichi Yasunami
Ishan Goswami, Eleonora de Klerk, Phichitpol Carnese, Matthias Hebrok, Kevin Healy
Min Luo, Hui Zhang, Chaoke Bu, Zhiyong Peng, Guangchao Li, Zhao Zhou, Wen Ding, Yongwei Zheng, Yingyi He, Zhengbin Hu, Kunlin Pei, Chunfu Li
Hyo Sung Jung, Seyoung Koo, Miae Won, Seeun An, Haebeen Park, Jonathan Sessler, Jiyou Han, Jong Seung Kim
Sudip Paul, Masamitsu Sone, Ashwini Patil, Hisaya Kato, Yoshiro Maezawa, Motohiko Oshima, Masaki Fukuyo, Bahityar Rahmutulla, Yasuo Ouchi, Kyoko Tsujimura, Mahito Nakanishi, Atsushi Kaneda, Atsushi Iwama, Koutaro Yokote, Koji Eto, Naoya Takayama
Hana Najahi, Nicola Alessio, Tiziana Squillaro, Gea Oliveri Conti, Margherita Ferrante, Giovanni Di Bernardo, Umberto Galderisi, Imed Messaoudi, Sergio Minucci, Mohamed Banni
Jixian Xiong, Yuting Li, Xiangyu Tan, Tie Chen, Baohua Liu, Li Fu
Takeshi Fujimori, Yuki Shibayama, Takahiro Kanda, Kenta Suzuki, Daisuke Ogawa, Ryo Ishikawa, Kyuichi Kadota, Toru Matsunaga, Keisuke Miyake, Akira Nishiyama, Takashi Tamiya
Zhihua Chen, Yilin Lin, Suyong Lin, Xiaoyu Yang, Shao-Qin Chen
Maxime Fredon, Margaux Poussard, Sabeha Biichle, Francis Bonnefoy, Evan Seffar, Elodie Bôle-Richard, Florian Renosi, Romain Boidot, François Anna, Maria Loustau, Julien Caumartin, Philippe Saas, Eric Deconinck, Etienne Daguindeau, Xavier Roussel, Olivier Adotevi, Fanny Angelot-Delettre, Jeanne Galaine, Francne Garnache-Ottou
Roqaye Karimi, Amir Atashi, Mina Soufi Zomorrod, Monireh Agami, Mansoureh Ajami
Negin Samadi Kharajouei
Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc.
Céline Hervieu, Mireille Verdier, Gaëlle Bégaud, Niki Christou, Magali Sage, Julie Pannequin, Serge Battu, Muriel Mathonnet
Jingan Chen, Yi Liu, Jingwen Zhang, Haowei Liang, Ting Li, Li Yan, Li Zhou, Letian Shan, Hui Wang
Hitomi Nagayama, Jun Ooi
Li-E Zhu, Hui-Ping Huang, Yi-Peng Cai, Yan Wang, Bao-Hua Xu, Mao-Bai Liu, Xue-Mei Wu
Rajib Shome, Plaboni Sen, Siddhartha Sankar Ghosh
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting to be held in Washington, D.C. from May 16-19, 2022.
Background Relapse is the leading cause of death from myeloid malignancies after allogeneic hematopoietic stem cell transplantation (HSCT). Azacitidine has gained attention in recent years in the prophylaxis of relapsed refractory hematologic …
Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced …
It is known that Rho GTPases control different aspects of the biology of skin stem cells (SSCs). However, little information is available on the role of their upstream regulators under normal and tumorigenic conditions in this process. To address this …
… Given the important function of PTBP1 in directing lineage choice in diverse stem cell systems and the overall relevance of mRNA splicing in hematopoiesis, we hypothesized that PTBP1 might play a role as a regulator of posttranscriptional …
… To investigate the status of the T-cell compartment of UPN1 up to 51 years post-HSCT in the context of a stem cell boost at 37 years after HSCT, we aimed to combine detailed phenotyping with TCR repertoire analysis. Development of a T-cell-focused …
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right